Table 5.
Risk factors for tumor recurrence in HCC patients with portal vein invasion by univariate analysis
| Variables | Hazard ratio | 95% confidence interval | Pvalue |
|---|---|---|---|
| Gender - Female |
0.657 |
0.313–1.376 |
0.265 |
| Age |
0.973 |
0.946–1.000 |
0.052 |
| AFP |
1.000 |
1.000–1.000 |
0.005 |
| PIVKA-II |
1.001 |
1.000–1.001 |
0.128 |
| Locoregional therapy |
1.495 |
0.848–2.634 |
0.165 |
| White blood cells |
0.961 |
0.835–1.107 |
0.582 |
| Hemoglobin |
1.010 |
0.853–1.195 |
0.909 |
| Platelet counts |
1.000 |
0.998–1.003 |
0.821 |
| INR |
6.056 |
0.254–144.219 |
0.266 |
| Albumin |
0.533 |
0.290–0.980 |
0.043 |
| Total bilirubin |
1.047 |
0.654–1.676 |
0.849 |
| AST |
1.005 |
0.999–1.011 |
0.103 |
| ALT |
1.002 |
0.996–1.008 |
0.565 |
| ALP |
1.002 |
0.995–1.008 |
0.643 |
| Creatinine |
0.427 |
0.091–2.004 |
0.281 |
| Estimated GFR |
1.015 |
0.997–1.033 |
0.102 |
| GGT |
1.000 |
0.998–1.001 |
0.739 |
| CRP |
1.133 |
1.028–1.249 |
0.012 |
| Operation (non-anatomical) |
1.473 |
0.863–2.515 |
0.156 |
| Hepatectomy (minor) |
0.922 |
0.367–2.315 |
0.863 |
| Maximum tumor size |
1.003 |
0.997–1.010 |
0.282 |
| Grade (3 and 4) |
0.627 |
0.311–1.267 |
0.194 |
| Cirrhosis |
1.426 |
0.879–2.314 |
0.150 |
| Capsule formation |
1.020 |
0.353–2.941 |
0.971 |
| Capsular invasion |
0.715 |
0.439–1.165 |
0.178 |
| Bile duct invasion |
0.752 |
0.302–1.873 |
0.540 |
| Serosa involvement |
5.863 |
1.372–25.058 |
0.017 |
| Intrahepatic metastasis |
1.787 |
1.098–2.910 |
0.020 |
| Multicentric occurrence |
0.048 |
0.00–195.191 |
0.474 |
| Margin (mm) | 1.006 | 0.986–1.026 | 0.566 |
AFP, Alpha-fetoprotein; ALP, Alkaline phosphate; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CRP, C-reactive protein; GFR, Estimated glomerular filtration rate; GGT, Gamma-glutamyl transferase; INR, International normalized ratio; PIVKA-II, Protein induced by vitamin K antagonist-II.